# BRAF V600E mutation

Source: https://onco.cc/terms/braf-v600-mutation/  
OnCo record `braf-v600-mutation` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A single spelling change in the BRAF gene that jams a growth switch permanently on. It is found in half of melanomas and in some colon, thyroid, lung and brain tumours, and is treated with a BRAF pill plus a MEK pill.

## Summary

V600E (valine to glutamate at position 600) is the commonest BRAF mutation; class II and III mutations behave differently and resist the same drugs. Dabrafenib-trametinib, encorafenib-binimetinib and vemurafenib-cobimetinib treat metastatic and adjuvant melanoma, with immunotherapy usually given first in metastatic disease (DREAMseq). Encorafenib-cetuximab treats BRAF-mutant colorectal cancer (BEACON), dabrafenib-trametinib has a tumour-agnostic approval including glioma and thyroid cancer, and the combination has moved into paediatric low-grade glioma. BRAF-mutant colorectal cancer is aggressive and often overlaps with MSI-high sporadic tumours.

## Fields

- Kind: Term
- Last checked: 2026-09-09
- Also known as: V600E; V600; BRAF V600E; BRAF V600; BRAF-mutant; BRAF-mutated; BRAF mutation; BRAF-mutant melanoma; BRAF/MEK; BRAF + MEK; class II BRAF; class III BRAF; BRAF inhibitor; MEK inhibitor; BRAF inhibitors; MEK inhibitors

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/BRAF_(gene)
- Wikipedia: https://en.wikipedia.org/wiki/BRAF_(gene)

## Connected records

- terms: [Driver mutation](https://onco.cc/terms/driver-mutation/), [MLH1 promoter methylation (sporadic versus Lynch mismatch repair loss)](https://onco.cc/terms/mlh1-promoter-methylation/), [Tumour-agnostic (tissue-agnostic) approval](https://onco.cc/terms/tumour-agnostic/), [Tyrosine kinase inhibitor (TKI)](https://onco.cc/terms/tki-term/)
- cancers: [BRAF V600-mutant melanoma](https://onco.cc/cancers/braf-v600-melanoma/), [BRAF V600E-mutant non-small-cell lung cancer](https://onco.cc/cancers/braf-v600e-nsclc/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Erdheim-Chester disease](https://onco.cc/cancers/erdheim-chester-disease/), [Erdheim-Chester disease, Rosai-Dorfman disease and other histiocytic neoplasms](https://onco.cc/cancers/histiocytoses/), [KRAS wild-type pancreatic ductal adenocarcinoma](https://onco.cc/cancers/kras-wild-type-pdac/), [Melanoma](https://onco.cc/cancers/melanoma/), [Multisystem Langerhans cell histiocytosis (with or without risk-organ involvement)](https://onco.cc/cancers/lch-multisystem/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Single-system Langerhans cell histiocytosis (bone, skin or one other organ)](https://onco.cc/cancers/lch-single-system/), [Thyroid cancer](https://onco.cc/cancers/thyroid/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- targets: [BRAF](https://onco.cc/targets/braf/)
- drugs: [Vemurafenib](https://onco.cc/drugs/vemurafenib/)
- trials: [BRF113928 cohort C (dabrafenib with trametinib, untreated BRAF V600E)](https://onco.cc/trials/brf113928/), [PHAROS](https://onco.cc/trials/pharos/), [TADPOLE (CDRB436G2201)](https://onco.cc/trials/tadpole/)
- biomarkers: [BRAF class II and class III mutations (non-V600)](https://onco.cc/biomarkers/braf-class-ii-iii/), [BRAF fusion or rearrangement](https://onco.cc/biomarkers/braf-fusion/), [BRAF V600E (and V600K)](https://onco.cc/biomarkers/braf-v600e/)

---
JSON: https://onco.cc/api/v1/entities/braf-v600-mutation.json